San Francisco, US Tuesday, February 18, 2025, 09:00 Hrs [IST] ...

and non-small cell lung cancer, has demonstrated that cadonilimab exhibits breakthrough efficacy across "broad population", demonstrating clinically meaningful positive outcomes for PD-L1 high ...

The EC approval of these two indications is based on results from the LITESPARK-004 and LITESPARK-005 trials, respectively, ...

In September 2024, the cadonilimab regimen for the first-line treatment of advanced ... and non-small cell lung cancer, has demonstrated that cadonilimab exhibits breakthrough efficacy across "broad ...

Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell ... to first-line chemo in PD-L1-high patients.

HONG KONG, Jan. 22, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the prestigious medical journal Nature Medicine published the results of the ...

Serplulimab is the world's first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC Serplulimab is the first and only anti-PD-1 mAb approved in the European Union (EU) ...